Bharat Parenterals Ltd share price slipped 1.57% to Rs 1441.7 after the company's net profit plunged by 56.37% to Rs 3.56 crore, while revenue from operations eased by 5.90% to Rs 93.74 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.82 lakh crore, gaining 4.98%. It has inched up 0.66% over last one week and heading higher by 11.72% in last one month while the market capitalization of Bharat Parenterals Ltd has softened by 2.27% and 20.64% in the same period respectively. Profit before tax (PBT) of Bharat Parenterals Ltd stood at Rs 1.49 crore in Q2 FY26, plunging by 158.43% year-on-year, and tumbling by 82.20% quarter-on-quarter. EBITDA came in at Rs 7 crore, nosediving by 41.54% YoY and tanking 279.04% sequentially. Total expenses contracted by 13.69% to Rs 93.89 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 40.5 crore, registering a fall of 21.13% YoY, while employee benefits expense was at Rs 18.84 crore, inching up 2.06% YoY. For the TTM ended FY26, revenue from operations surged 30.30% to Rs 340.38 crore, while net profit tanked by 515.60% to Rs 43.68 crore, compared to previous TTM. EBITDA soared by 4770% to Rs 8.92 crore, and PBT collapsed by 281.36% to Rs 33.95 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 27.25 crore in FY26, as against Rs 4.71 crore in FY25. Bharat Parenterals Ltd declined by 3% in last one year, performing in line with the benchmark BSE Sensex which has eased by 3.20% during the same period.
